We’ve detected that you are using an outdated browser. For Windows users, this site is best experienced using Google Chrome, Firefox, or Microsoft Edge
REXULTI® (brexpiprazole): Demonstrated safety profile
Adverse reactions in ≥2% of patients treated with REXULTI and greater than placebo from two 12-week pivotal trials across all doses
a1 mg once day REXULTI dosage is not a recommended dosage for the treatment of agitation associated with dementia due to Alzheimer’s disease.
bDizziness and Vertigo are grouped to Dizziness
cSedation and somnolence are group to somnolence.
dInitial insomnia and insomnia are grouped to insomnia
Most common adverse reaction occurring in ≥4% of patients and at least twice the rate of placebo were nasopharyngitis and dizziness.
At a dose 4 times the MRHD for the treatment of agitation associated with dementia due to Alzheimer's disease, REXULTI does not prolong the QTc interval to any clinically relevant extent.
MRHD, Maximum Recommended Human Dose.
REXULTI vs placebo: Similar discontinuation rates due to adverse reactions from two 12-week pivotal trials across all doses
Approximately 95% of patients remained on treatment without discontinuation due to adverse reactions, whether treated with REXULTI or placebo.
Continue exploring REXULTI
Learn about once-daily dosing and the titration schedule.
View results from 2 clinical trials for REXULTI.